United Therapeutics (NASDAQ:UTHR) CEO Sells $5,056,280.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Tuesday, July 21st. The stock was sold at an average price of $532.24, for a total transaction of $5,056,280.00. Following the sale, the chief executive officer owned 324,443 shares in the company, valued at approximately $172,681,542.32. The trade was a 2.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $525.82 on Friday. The company has a market capitalization of $22.32 billion, a P/E ratio of 19.41, a P/E/G ratio of 1.75 and a beta of 0.58. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35. The firm’s 50 day simple moving average is $544.65 and its two-hundred day simple moving average is $532.54.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period last year, the company earned $6.63 earnings per share. On average, sell-side analysts anticipate that United Therapeutics Corporation will post 26.65 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in UTHR. Torren Management LLC bought a new stake in shares of United Therapeutics in the fourth quarter worth about $26,000. Activest Wealth Management boosted its stake in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares during the last quarter. Entrust Financial LLC purchased a new position in United Therapeutics during the 4th quarter valued at approximately $31,000. International Assets Investment Management LLC grew its holdings in United Therapeutics by 426.7% during the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 64 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB increased its stake in United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 49 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

UTHR has been the subject of a number of analyst reports. Royal Bank Of Canada increased their price target on United Therapeutics from $701.00 to $704.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research note on Thursday, June 11th. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Raymond James Financial started coverage on United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 target price on the stock. Finally, Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $648.33.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.